
Tim
7.1K posts






Novavax is so good that Pfizer wants to license it lol reuters.com/business/healt…



📢Huge news from Novavax today, Pfizer just entered into a licensing agreement which will allow them to use Novavax’s Matrix-M adjuvant in their products. This is similar to the agreement that was signed with Sanofi back in 2024, minus the Nuvaxovid commercialization. Novavax has been talking a lot about this for the past few months, noting that they had signed 2 MTAs (material transfer agreements) with top-10 pharma companies, which essentially just means that they were allowed to investigate the use of Matrix-M. Now, we have confirmation that one of those companies is Pfizer, and that they’re taking the next step to potentially including Matrix-M in their vaccines. Idk about you…but after 4 years of fighting this battle, what I’m hearing here is that Pfizer is finally admitting: 1. They weren’t able to get rid of Novavax as a company or a product…although they certainly tried…so they’re deciding not to ignore the elephant in the room any longer. 2. The elephant in the room is that their COVID-19 product is worse than Nuvaxovid…because why on earth would you need to invest in part of Nuvaxovid if that wasn’t the case? But that’s fine…we can put all of that in the past. This is legitimately really great news, and Matrix-M will hopefully be able to save more lives here as part of Pfizer’s portfolio, just like it’s been doing in Nuvaxovid and in the R21 Malaria vaccine in Africa. We can all finally get to work on advancing vaccines with next-generation adjuvants that actually work, and restoring the trust of the American people @Novavax @pfizer @sanofi @SecKennedy @US_FDA @FDACBER @DrMakaryFDA @CDCgov @RWMaloneMD @KMilhoanMDPhD








#NEWS: Novavax has entered into a non-exclusive license agreement with @pfizer for use of Novavax’s Matrix-M® adjuvant for up to two disease areas. This new partnership shows our corporate strategy in action, and adds to the successful collaboration we have with Sanofi, among other major companies. We’re excited to be executing on our strategy to drive incremental value from partnerships and R&D innovation, with the potential to create new or improve existing products using Novavax’s differentiated technology platform. Ultimately, these partnerships increase access for the people who could benefit from products built with our technology and importantly drive incremental value for investors and for global public health. Visit ir.novavax.com to get details on the potential value we are building with this partnership, including $30 million upfront, up to $500 million in milestone payments and more. We’re excited to work with you, Pfizer. Read more: ir.novavax.com/press-releases…



📢Huge news from Novavax today, Pfizer just entered into a licensing agreement which will allow them to use Novavax’s Matrix-M adjuvant in their products. This is similar to the agreement that was signed with Sanofi back in 2024, minus the Nuvaxovid commercialization. Novavax has been talking a lot about this for the past few months, noting that they had signed 2 MTAs (material transfer agreements) with top-10 pharma companies, which essentially just means that they were allowed to investigate the use of Matrix-M. Now, we have confirmation that one of those companies is Pfizer, and that they’re taking the next step to potentially including Matrix-M in their vaccines. Idk about you…but after 4 years of fighting this battle, what I’m hearing here is that Pfizer is finally admitting: 1. They weren’t able to get rid of Novavax as a company or a product…although they certainly tried…so they’re deciding not to ignore the elephant in the room any longer. 2. The elephant in the room is that their COVID-19 product is worse than Nuvaxovid…because why on earth would you need to invest in part of Nuvaxovid if that wasn’t the case? But that’s fine…we can put all of that in the past. This is legitimately really great news, and Matrix-M will hopefully be able to save more lives here as part of Pfizer’s portfolio, just like it’s been doing in Nuvaxovid and in the R21 Malaria vaccine in Africa. We can all finally get to work on advancing vaccines with next-generation adjuvants that actually work, and restoring the trust of the American people @Novavax @pfizer @sanofi @SecKennedy @US_FDA @FDACBER @DrMakaryFDA @CDCgov @RWMaloneMD @KMilhoanMDPhD













